Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

Bouros D, Hatzakis K, Labrakis H and Zeibecoglou K: Association of malignancy with diseases causing interstitial pulmonary changes. Chest. 121:1278–1289. 2002. View Article : Google Scholar : PubMed/NCBI

Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K and Homma S: Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anticancer therapy. Respirology. 15:88–92. 2010. View Article : Google Scholar

Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S and Gemma A: The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 71:70–74. 2011. View Article : Google Scholar : PubMed/NCBI

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar

Chugai Pharmaceutical Co, Ltd.: http://chugai-pharm.jp/hc/ss/pr/safe/report/ava/index.html. Accessed July 26, 2012.

Usui K, Katou Y, Furushima K, Tanaka Y, Tanai C and Ishihara T: Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. Jpn J Clin Oncol. 41:498–502. 2011. View Article : Google Scholar : PubMed/NCBI

Tamura J, Nakauchi M, Nakayama Y, Kitaguchi K, Sakikubo M, Ura K, Taira K, Ohe H, Yoshikawa A, Ishigami S and Baba N: A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer. Gan To Kagaku Ryoho. 36:2665–2668. 2009.(In Japanese).

Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N and Fukuoka M; JO19907 Study Group: Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 76:362–367. 2012. View Article : Google Scholar : PubMed/NCBI

Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M and du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 365:1079–1087. 2011. View Article : Google Scholar : PubMed/NCBI

Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P and von Pawel J: A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer. Ann Oncol. 22:1374–1381. 2011. View Article : Google Scholar : PubMed/NCBI

US National Institutes of Health: Lume-Lung 1: BIBF 1120 plus docetaxel as compared to placebo plus docetaxel in 2nd line non-small cell lung cancer. http://clinicaltrials.gov/ct2/show/NCT00805194. Accessed July 26, 2012.

US National Institutes of Health: Lume-Lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC. http://clinicaltrials.gov/ct2/show/NCT00806819. Accessed July 26, 2012.